PRMT5 and neoplasm: Treatment of mantel cell lymphoma (MCL) cell lines with the orally available PRMT5 inhibitor EPZ015666 (GSK3235025) led to inhibition of SmD3 methylation and cell death, while oral administration in MCL xenograft mouse models demonstrated dose-dependent anti-tumor activity [116].